Orexigen Therapeutics Inc

Orexigen Therapeutics — JMP Securities Healthcare Conference 2011

25 slides from Orexigen Therapeutics's conference presentation, Sep 27, 2011

  1. Slide 1: JMP Securities Healthcare Conference

    Slide 1: JMP Securities Healthcare Conference

    JMP Securities Healthcare Conference JMP Securities Healthcare Conference September 28, 2011 September 28, 2011 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expre

  3. Slide 3: Orexigen Strategic Summary

    Slide 3: Orexigen Strategic Summary

    Orexigen Strategic Summary Regulatory Path Clarified Obesity Unmet Need Orexigen Position Orexigen Strategic Summary Clear path to approval defined by FDA’s OND Clear path to approval defined by FDA’s OND Time, cost and probability of success make approval Time, cost and probability of success make

  4. Slide 4: Experienced Management Team with a Strong Balance Sheet

    Slide 4: Experienced Management Team with a Strong Balance Sheet

    Experienced Management Team with a Strong Balance Sheet End of Q2 Cash and Investments Balance of $69.7m Currently Low Operating Expense Base and No Debt Experienced Management Team with a Strong Balance Sheet Michael Narachi, President and CEO 20-Year Veteran of Amgen – Including: GM of Anemia Busi

  5. Slide 5: Regulatory Update

    Slide 5: Regulatory Update

    Regulatory Update Orexigen Position Global Need

  6. Slide 6: The Orexigen Story – Two Years of Successes and Setbacks

    Slide 6: The Orexigen Story – Two Years of Successes and Setbacks

    The Orexigen Story – Two Years of Successes and Setbacks, but a Clear Path to Approval Has Emerged Filed NDA NDA Accepted by FDA Results Published in The Lancet & Obesity Signed Takeda Partnership Positive Advisory Committee Meeting The Orexigen Story – Two Years of Successes and Setbacks, but a Cle

  7. Slide 7: FDA Has Provided Guidance on Critical Elements for Feasible Trial

    Slide 7: FDA Has Provided Guidance on Critical Elements for Feasible Trial

    FDA Has Provided Guidance on Critical Elements for Feasible Trial FDA Has Provided Guidance on Critical Elements for Feasible Trial Goal of trial is to demonstrate that the risk of CV events is not unacceptably high Primary endpoint is major CV events (MACE = CV death, MI, stroke) Enrolled patient p

  8. Slide 8: Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates

    Slide 8: Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates

    Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates Typical Phase 3 Trial Approach for Contrave CVOT* Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates Comprehensive evaluation of efficacy and general safety Targeted clinical question allows focused

  9. Slide 9: Probability of Success at Interim Analysis is High

    Slide 9: Probability of Success at Interim Analysis is High

    Probability of Success at Interim Analysis is High Probability of Success at Interim Analysis is High Bupropion well characterized in >50M patients over >25 years – Large prospective patient registries (up to 10,000 patients) and examination of AERS have not identified evidence of increased clinical

  10. Slide 10: Estimated Timing of Key Events That Could Deliver a 2014 Approval

    Slide 10: Estimated Timing of Key Events That Could Deliver a 2014 Approval

    Estimated Timing of Key Events That Could Deliver a 2014 Approval Development Milestone Estimated Time Estimated Timing of Key Events That Could Deliver a 2014 Approval Finalize Protocol Details and Begin CVOT 7-9 months Enroll and Accrue 87 CV Events for Interim Analysis 18-20 months Time to Prepar

  11. Slide 11: Global Need

    Slide 11: Global Need

    Regulatory Update Orexigen Position Global Need

  12. Slide 12: Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm

    Slide 12: Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm

    Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm 16% 34% 43% Serious Disease Attributable to Obesity Treatment Options Needed Increase in Obesity Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm T2DM, Driven by Obesity, Is an Epidemic in Adults in the U.S. May

  13. Slide 13: World Wide Obesity Prevalence Projected to Increase Over the Next Decade

    Slide 13: World Wide Obesity Prevalence Projected to Increase Over the Next Decade

    World Wide Obesity Prevalence Projected to Increase Over the Next Decade World Wide Obesity Prevalence Projected to Increase Over the Next Decade n= ~473M people n= ~473M people n= ~655M people n= ~655M people % Growth % Growth 81% 81% 17% 17% 38% 38% 20% 20% 41% 41% Region Region Source: EuroMonito

  14. Slide 14: Orexigen Position

    Slide 14: Orexigen Position

    Regulatory Update Orexigen Position Global Need

  15. Slide 15: Contrave Keys to Commercial Success

    Slide 15: Contrave Keys to Commercial Success

    Contrave Keys to Commercial Success Blockbuster Market Size Market Growth Significant Unmet Need – Limited Competition Contrave: Differentiated Profile Takeda: Well Established and Resourced Majority of Obese are Untreated in an Environment of Limited Treatment Options Contrave Keys to Commercial Su

  16. Slide 16: Typical Response to Weight Loss Therapy is not Uniform

    Slide 16: Typical Response to Weight Loss Therapy is not Uniform

    Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) - - - - N =471 N=471 for COR-I subjects treated with Contrave

  17. Slide 17: Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response

    Slide 17: Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response

    Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response COR-I Weight Loss Distribution (Contrave32) Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response Our Focus: Patients Who Lose 5% <5% weight loss N=471 for COR-I subjects tre

  18. Slide 18: Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy

    Slide 18: Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy

    Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy Appropriate BMI Motivated to Adhere to Lifestyle Change Inadequate Response to Diet & Exercise Select Responders for Continued Treatment Reinf

  19. Slide 19: Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss

    Slide 19: Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss

    Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss Weight Loss Distribution 0% - 5% Weight loss 10% - 15% Weight Loss Avg Wt Loss = 26.7 lbs >15% Wt Loss Avg Wt Loss = 43.9 lbs Weight Gain 5% - 10% Weight Loss Avg Wt Loss = 17.0 lbs Contrave Early Responders Go on to Achiev

  20. Slide 20: Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters

    Slide 20: Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters

    Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Contrave32 N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Improvement (Standardized Mean Change from Baseline) Placebo N=254 -11.3% -8.6% -9.5

  21. Slide 21: Contrave: Well Characterized Safety Profile

    Slide 21: Contrave: Well Characterized Safety Profile

    Contrave: Well Characterized Safety Profile Delivers Safety Experience Consistent with 20+ Year History of Underlying Agents Known Areas of Focus for Development Program – CV Effects, Seizure, Psychiatric Effects, Creatinine General Safety Profile Established in >4500 Patients with Single Approval D

  22. Slide 22: Takeda is the Ideal Partner for Contrave

    Slide 22: Takeda is the Ideal Partner for Contrave

    Takeda is the Ideal Partner for Contrave SUCCESSFUL BRAND BUILDER Actos ~$3B in U.S. Sales in 2009 Prevacid ~$3B in U.S. Sales in 2009 SCALE Top 15 Pharma Significant U.S. Presence Primary Care Focus COMMITMENT TO OBESITY Partnership with Amylin Stated Strategy DOMAIN EXPERIENCE Leader in Cardiometa

  23. Slide 23: Competitive Product Profile Attractive to Patients

    Slide 23: Competitive Product Profile Attractive to Patients

    Competitive Product Profile Attractive to Patients Women Dominate the Market No Addictive Concerns Responders Maintained Meaningful Weight Loss 73% Competitive Product Profile Attractive to Patients No Abuse Liability No DEA Limitations on Distribution Expected 73% Sources: Orexigen Quantitative Mar

  24. Slide 24: Orexigen Strategic Summary

    Slide 24: Orexigen Strategic Summary

    Orexigen Strategic Summary Regulatory Path Clarified Obesity Unmet Need Orexigen Position Orexigen Strategic Summary Clear path to approval defined by FDA’s OND Clear path to approval defined by FDA’s OND Time, cost and probability of success make approval Time, cost and probability of success make

  25. Slide 25: Orexigen

    Slide 25: Orexigen

    ts OREXIGEN

Source: SEC EDGAR · 8-K filed Sep 27, 2011

More decks from Orexigen Therapeutics Inc